retatrutide legal status A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity | European Journal of Clinical Pharmacology VisualAbstract: Retatrutide reduces body weight

The NEJM phase 2 obesity trial reports published retatrutide study design, dose groups, and safety findings

Retatrutide has developed one of the most rapidly growing pre-clinical research profiles of any metabolic peptide currently in active study: Pre-clinical metabolic research in obese animal models has reported body weight and fat mass reductions with Retatrutide that exceed those observed with dual-receptor compounds including Tirzepatide at comparable doses and suggesting that the addition of glucagon receptor engagement to combined GLP-1/GIP agonism produces meaningfully greater metabolic effects in experimental settings

Unlike many hypoglycemic drugs, GLP-1 regulates glucose levels in a glucose-dependent manner, significantly reducing the risk of hypoglycemia

Additionally, gastrointestinal side effects common with GLP-1-based therapiesincluding nausea, vomiting, and diarrheamay reduce interest in sexual activity during the initial treatment period or dose escalation phases

For their findings, which havent been published yet in a peer-reviewed journal, researchers developed a machine-learning gene risk score to predict hungry gut. This occurs when someone eats a meal but feels hungry again after an hour or two due to their stomach emptying quickly